HC Wainwright Has Pessimistic Outlook of TSE:FRX Q3 Earnings

Fennec Pharmaceuticals Inc. (TSE:FRX) – Stock analysts at HC Wainwright decreased their Q3 2026 earnings per share estimates for shares of Fennec Pharmaceuticals in a research note issued on Wednesday, September 9th. HC Wainwright analyst R. Selvaraju now forecasts that the biopharmaceutical company will earn $0.08 per share for the quarter, down from their prior estimate of $0.14. The consensus estimate for Fennec Pharmaceuticals’ current full-year earnings is $0.60 per share. HC Wainwright also issued estimates for Fennec Pharmaceuticals’ Q4 2026 earnings at $0.12 EPS, FY2026 earnings at $0.29 EPS, Q1 2027 earnings at $0.18 EPS, Q2 2027 earnings at $0.26 EPS and FY2027 earnings at $1.20 EPS.

Fennec Pharmaceuticals Price Performance

Shares of FRX opened at C$17.10 on Thursday. The firm has a market capitalization of C$599.65 million, a PE ratio of -142.50 and a beta of 3.72. The company’s 50-day moving average is C$15.55 and its 200-day moving average is C$12.70. Fennec Pharmaceuticals has a fifty-two week low of C$7.59 and a fifty-two week high of C$17.64.

Institutional Trading of Fennec Pharmaceuticals

A hedge fund recently bought a new stake in Fennec Pharmaceuticals stock. Cornerstone Capital Inc. purchased a new stake in Fennec Pharmaceuticals Inc. (TSE:FRX) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 105,000 shares of the biopharmaceutical company’s stock, valued at approximately $1,129,000. Cornerstone Capital Inc. owned approximately 0.30% of Fennec Pharmaceuticals at the end of the most recent quarter. Institutional investors own 15.40% of the company’s stock.

Insider Activity

In other news, insider Robert Christopher Andrade sold 106,844 shares of the company’s stock in a transaction that occurred on Thursday, August 27th. The stock was sold at an average price of C$16.63, for a total value of C$1,776,815.72. Following the transaction, the insider owned 217,675 shares of the company’s stock, valued at approximately C$3,619,935.25. This represents a 32.92% decrease in their ownership of the stock. Also, insider Pierre Sayad sold 12,000 shares of the stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of C$17.18, for a total value of C$206,160.00. Following the transaction, the insider owned 9,519 shares in the company, valued at approximately C$163,536.42. This trade represents a 55.76% decrease in their position. 16.20% of the stock is owned by corporate insiders.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc is a specialty pharmaceutical company committed to the fight against ototoxicity in cancer patients who receive cisplatin-based chemotherapy. Fennec is focused on the commercialization of PEDMARK® to reduce the risk of platinum-induced ototoxicity in cancer patients. PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and United Kingdom ( U.K. ) approval in October 2023 under the brand name PEDMARQSI®. In March 2024, Fennec entered into an exclusive licensing agreement under which Norgine Pharmaceuticals Ltd., a leading European specialist pharmaceutical company, with rights to commercialize PEDMARQSI® in Europe, U.K., Australia and New Zealand.